Thousands Could Benefit from New Take-at-Home Treatment for Advanced Prostate Cancer
NICE recommended talazoparib (Talzenna by Pfizer) combined with enzalutamide for adults with metastatic castration-resistant prostate cancer (mCRPC) who cannot undergo chemotherapy or tolerate abiraterone plus prednisolone.
The once-daily pill is available on the NHS in England from January 23, 2026, benefiting around 2,400 people.
Clinical trials showed improved overall survival (45.8 months vs. 37 months) and progression-free survival (33.1 months vs. 19.5 months) compared to enzalutamide alone.
Talazoparib blocks DNA repair in cancer cells, causing cell death, and offers convenience as a take-at-home treatment.
This is the third recent NICE recommendation for metastatic prostate cancer treatments.